# Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)

Source: https://onco.cc/trials/nct05704244/  
OnCo record `nct05704244` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of FE 999326 in bladder & urothelial cancer, run by Ferring Pharmaceuticals, active and no longer recruiting.

## Summary

Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) is a phase 3 interventional study registered as NCT05704244 by Ferring Pharmaceuticals, with 25 participants enrolled, started 2022-12-21 and due to reach its primary completion in 2029-11-30. Interventions recorded: FE 999326.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05704244
- Phase: 3
- Setting: A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
- Sponsor: Ferring Pharmaceuticals
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT05704244: https://clinicaltrials.gov/study/NCT05704244

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [Ferring Pharmaceuticals](https://onco.cc/companies/ferring/)

---
JSON: https://onco.cc/api/v1/entities/nct05704244.json